NCT00532467

Multiple Dose Safety Study of SRX251 Capsules in Healthy Volunteers

Phase I, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic Study of SRX251 Capsules in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Azevan Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study is the second study to evaluate SRX251 in healthy volunteers and it represents the first multiple dose study. The primary objective of this study is to evaluate the safety and tolerability of escalating multiple oral doses of SRX251 capsules for 5 days in healthy adult volunteers. Levels of the drug in blood plasma will also be determined.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	SRX251

Timeline

• Start date: 2007-09-01
• Primary completion: 2008-02-01
• Completion: 2008-02-01
• First posted: 2007-09-20
• Last updated: 2008-03-13

Locations

1 site across 1 country: United States